Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Quest Partners LLC

Quest Partners LLC grew its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 138.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,635 shares of the company’s stock after purchasing an additional 7,928 shares during the quarter. Quest Partners LLC’s holdings in Syndax Pharmaceuticals were worth $280,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Sei Investments Co. boosted its stake in Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after purchasing an additional 991 shares during the last quarter. California State Teachers Retirement System boosted its stake in Syndax Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock worth $1,822,000 after purchasing an additional 1,150 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in Syndax Pharmaceuticals by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after purchasing an additional 1,496 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of Syndax Pharmaceuticals by 28.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock worth $171,000 after acquiring an additional 1,587 shares during the period.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $19.12 on Friday. The firm has a market capitalization of $1.63 billion, a PE ratio of -5.94 and a beta of 0.91. The firm’s 50-day moving average is $21.16 and its two-hundred day moving average is $21.35. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. Syndax Pharmaceuticals’s revenue for the quarter was up 3499999990.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.64) EPS. Analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Analysts Set New Price Targets

SNDX has been the topic of several analyst reports. Citigroup lifted their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, June 14th. Barclays lifted their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. reduced their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Stifel Nicolaus lifted their price target on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, June 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $35.33.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).